VIRNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31

Vir Biotechnology, Inc.

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026

$10.21+0.25 (+2.51%)

Close on Oct 19, 2026

Market cap: $1.72B
P/E (TTM): –
Dividend yield: –

Vir Biotechnology, Inc. income statement

Annual Quarterly TTM

Millions of USD, except per-share data. Shares in millions.

Line item	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31	FY 2020 2020-12-31	FY 2019 2019-12-31	FY 2018 2018-12-31	FY 2017 2017-12-31
Revenue	69	74	86	1,616	1,095	76	8.09	11	2.71
Cost of Revenue	0.03	0.85	2.77	146	66	0	0	–	–
Gross Profit	69	73	83	1,469	1,030	76	8.09	–	–
Research & Development	456	506	580	475	448	302	148	100	63
Selling, General & Admin	92	119	174	162	161	71	38	–	–
General & Administrative	–	–	–	–	–	71	38	29	22
Operating Expenses	–	–	–	–	–	373	186	129	84
Total Costs & Expenses	548	661	770	783	675	373	186	–	–
Operating Income	-479	-587	-684	833	421	-297	-178	-119	-81
Interest & Investment Income	40	72	87	28	–	–	8.51	2.54	0.64
Other Non-Operating Income	42	64	56	-79	129	-1.63	-3.45	2.33	0.72
Merger & Restructuring Charges	-0.18	35	14	0	–	–	–	–	–
Asset Impairment Charges	0	0	0	0	0	0	0	–	–
Gain (Loss) on Sale of Assets	–	–	–	–	–	–	-0.35	-0.20	–
Pretax Income	-438	-523	-628	754	550	-299	-175	-116	-81
Income Tax Expense	0.22	-1.15	-13	238	21	0.05	0.15	-0.48	-11
Net Income incl. Noncontrolling Interests	-438	-522	-615	516	529	-299	-175	-116	-70
Minority Interest in Earnings	0	0	-0.06	0	–	–	–	–	–
Net Income	-438	-522	-615	516	529	-299	-175	-116	-70
Net Income to Common	–	–	-615	516	529	–	–	–	–
EPS (Basic)(per share)	-3.16	-3.83	-4.59	3.89	4.07	-2.51	-5.76	-15.12	-32.45
EPS (Diluted)(per share)	-3.16	-3.83	-4.59	3.83	3.96	-2.51	-5.76	-15.12	-32.45
Shares Outstanding (Basic, Weighted)(shares)	139	136	134	133	130	119	30	7.67	2.15
Shares Outstanding (Diluted, Weighted)(shares)	139	136	134	135	133	119	30	7.67	2.15
EBITDA	-468	-573	-665	840	426	-293	-175	-117	-81

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Jun 30, 2026

Profitability, TTM

Gross margin: 22.6%
Operating margin: -92.4%
Net margin: -83.0%
Return on equity, FY2025: -45.7%

Financial strength

Current ratio: 6.04
Debt to equity: –
Debt to assets: –
Cash to current liabilities: 293.5%

Valuation

P/E ratio: –
Price to sales: 5.69
Price to book: 1.75
Dividend yield: –